Novartis reports positive results for Aimovig in phase 2 episodic migraine trial
Novartis said that a five-year phase 2 clinical trial of migraine prevention drug Aimovig (erenumab-aooe) has delivered strong long-term safety and efficacy results in patients ... Read More
Nestlé to fully own Aimmune Therapeutics through $2bn deal
Nestlé will take full ownership of Aimmune Therapeutics, the developer of FDA approved peanut allergy drug Palforzia, by acquiring the remaining stake of 74.4% in ... Read More
Novartis bags Kesimpta FDA approval for relapsing forms of MS
Kesimpta FDA approval for RMS: Novartis has bagged approval from the US Food and Drug Administration (FDA) for its blood cancer drug Kesimpta (ofatumumab, formerly OMB157) ... Read More
Northway Biotechpharma to manufacture Memo’s Covid1-9 drug MTX-COVAB
Memo Therapeutics (MTx), a Swiss biotech company, has entered into a partnership with Northway Biotechpharma, under which the latter will manufacture the former's MTX-COVAB - ... Read More
UCB signs $2bn worth deal with Roche for AD drug candidate UCB0107
Belgian pharma company UCB has signed a global exclusive license deal worth up to $2 billion for its Alzheimer's Disease drug candidate (AD drug candidate) ... Read More
Nestlé Nespresso to expand Romont production center with $170m investment
Nestlé Nespresso (Nespresso) will invest CHF160 million ($170.28 million) to expand its Romont production center in Switzerland to address the growing consumer demand for its ... Read More
Barry Callebaut wraps up acquisition of GKC Foods (Australia)
Barry Callebaut acquisition of GKC Foods : Switzerland-based Barry Callebaut Group has wrapped up its previously announced acquisition of GKC Foods (Australia), a producer of ... Read More
Roche acquires DNA sequencing technology company Stratos Genomics
Roche acquisition of Stratos Genomics : Swiss pharma giant Roche has acquired US-based early-stage DNA sequencing technology company Stratos Genomics for an undisclosed price. The ... Read More
Construction begins on Merck Biotech Development Center in Switzerland
Merck has broken ground on the €250 million Merck Biotech Development Center, a new biotech development facility in Switzerland at Corsier-sur-Vevey. The new facility will ... Read More
ForaCare Suisse launches FOR A 6 GTel diabetes monitoring device
ForaCare Suisse has launched a new cellular multi-functional diabetes monitoring device FORA 6 GTel based on its Lab in the Pocket technology. The Lab in ... Read More